Decera Clinical Education Oncology Podcast

Decera Clinical Education
  • 4.9 (10)
  • Courses
  • Updated Biweekly

Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Decera Clinical Education. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.

  1. HNSCC: Current and Emerging Therapeutic Strategies

    5d ago

    HNSCC: Current and Emerging Therapeutic Strategies

    In this episode, Dr Aarti Bhatia and Dr Deborah Wong discuss the rapidly evolving treatment landscape for recurrent, metastatic, and locally advanced head and neck squamous cell carcinoma (HNSCC), including the growing role of immune checkpoint inhibitors, perioperative treatment strategies, EGFR-targeted bispecific antibodies, antibody–drug conjugates, HPV-targeted vaccines, and novel radiosensitizers. The discussion also explores emerging phase III clinical trials, treatment sequencing considerations, and future precision oncology approaches for HPV-positive and HPV-negative patients with head and neck cancer. Presenters: Aarti Bhatia, MD, MPH Associate Professor of Medicine (Medical Oncology) Clinical Research Team Leader, Head and Neck Cancers Program Yale Cancer Center New Haven, Connecticut Deborah J. Wong, MD, PhD Director, Head and Neck Medical Oncology Program Associate Clinical Professor of Medicine Division of Hematology/Oncology University of California, Los Angeles (UCLA) Los Angeles, California Link to full program: https://bit.ly/49kViqg Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify.  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    26 min
  2. Navigating Relapsed/Refractory Multiple Myeloma: Real-world Use of Bispecific Antibodies

    May 15

    Navigating Relapsed/Refractory Multiple Myeloma: Real-world Use of Bispecific Antibodies

    In this episode, hear Doris K. Hansen, MD, discuss the management of relapsed/refractory multiple myeloma with bispecific antibodies including: Practical differences among approved bispecific antibodies Toxicity profiles of approved bispecific antibodies When to refer patients for evaluation for immunotherapies Considerations for sequencing bispecific antibodies in the relapsed/refractory setting New findings with combination regimens with bispecific antibodies Program faculty: Doris K. Hansen, MD Assistant Member, Blood and Marrow Transplant and Cellular Immunotherapy H. Lee Moffitt Cancer Center & Research Institute Assistant Professor University of South Florida Morsani College of Medicine Tampa, Florida Link to program page:https://bit.ly/4nufxr2 Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    21 min
  3. Oncologists “On Call”: Our Practical Experiences to Optimizing Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma

    May 7

    Oncologists “On Call”: Our Practical Experiences to Optimizing Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma

    In this episode, Muhamed Baljevic, MD, FACP, and Johnathan Ticku, MD, discuss various strategies to optimize the use of bispecific antibodies in their practices for the treatment of R/R MM through patient monitoring, dosing in outpatient settings, and using tocilizumab and IVIG, among other management strategies.  Presenters:  Muhamed Baljevic, MD, FACP Associate Professor of Medicine Division of Hematology-Oncology Department of Medicine Director, Multiple Myeloma Program Director, Vanderbilt Amyloidosis Multidisciplinary Program (VAMP) Co-Chair, Scientific Review Committee, VICC Disease Team Lead, Plasma Cell Dyscrasias and Lymphomas Vanderbilt-Ingram Cancer Center Vanderbilt University Medical Center Nashville, Tennessee Jonathan Ticku, MD Medical Oncologist and Hematologist GU Oncology Lead, Mayo Clinic Health System Assistant Professor of Oncology, Mayo Clinic La Crosse, Wisconsin Link to full program: https://bit.ly/4u0xH6q Get access to all of our new podcasts by subscribing to the Decera Clinical Education Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    31 min
  4. Thrombotic Events and ET/PV: What You Should Know

    Apr 30

    Thrombotic Events and ET/PV: What You Should Know

    In this episode, hear Anthony Hunter, MD and Douglas Tremblay, MD discuss the various presentations of thrombotic events in patients with PV or ET including how thrombotic events may lead to diagnosis:  PV and ET increase the risk of both arterial and venous thrombotic events  Unusual thrombotic events  Thrombosis as initial presentation for MPN Case presentations Brief overview of thrombosis management Program faculty: Anthony M. Hunter, MD Associate Professor, Department of Hematology and Medical Oncology Leader, Myeloproliferative Neoplasm Program Medical Director, Rollins Immediate Care Center Winship Cancer Institute of Emory University, Leukemia Group Atlanta, Georgia Douglas Tremblay, MD Associate Professor of Medicine Division of Hematology/Oncology Tisch Cancer Institute Icahn School of Medicine at Mount Sinai New York, New York Link to obtain CME/CE credit: https://bit.ly/4egx4Rf Link to program page: https://bit.ly/3OPSASy Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    22 min
  5. Global Experts Discuss Current and Emerging Treatments for ET and PV

    Apr 30

    Global Experts Discuss Current and Emerging Treatments for ET and PV

    In this podcast episode, Ciro Rinaldi MD, PhD, and Alessandro M. Vannucchi, MD, discuss contemporary management of essential thrombocythemia (ET) and polycythemia vera (PV), as well as novel investigational approaches, including the following: Overview of current treatment paradigms for PV and ET Importance of shared decision-making and patient communication in determining treatment Current therapeutic areas of need in ET and PV Emerging investigational therapeutics Presenters: Ciro Rinaldi MD, PhD Chief Medical Officer, United Lincolnshire Teaching Hospital Honorary Professor of Haematology, University of Lincoln Honorary Professor De Montfort University Dubai Consultant Haematologist Lincoln, United Kingdom Alessandro M. Vannucchi, MD Professor of Hematology University of Florence Director of Hematology Department Director of Oncology Department Azienda Ospedaliera Universitaria Careggi Florence, Italy Content based on an online CME program supported by an educational grant from Merck. Link to full program:https://bit.ly/4u09lKd Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    17 min
  6. Global Experts Discuss Diagnostic Considerations in ET and PV

    Apr 29

    Global Experts Discuss Diagnostic Considerations in ET and PV

    In this podcast episode, Ciro Rinaldi, MD, PhD, and Alessandro M. Vannucchi, MD, as they discuss contemporary topics in diagnosing essential thrombocythemia (ET) and polycythemia vera (PV), including: Overview of diagnostic criteria for PV and ET Importance of bone marrow biopsy Degree of suspicion of PV/ET in patients presenting with thrombotic events Pearls of wisdom in diagnosis Presenters:  Ciro Rinaldi, MD, PhD Chief Medical Officer, United Lincolnshire Teaching Hospital Honorary Professor of Haematology, University of Lincoln Honorary Professor De Montfort University Dubai Consultant Haematologist Lincoln, United Kingdom Alessandro M. Vannucchi, MD Full Professor of Hematology University of Florence Director of Hematology Department Director of Oncology Department Azienda Ospedaliera Universitaria Careggi Florence, Italy Content based on an online CME program supported by an educational grant from Merck. Link to full program: https://bit.ly/4u09lKd Get access to all our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    15 min
  7. Experts Discuss Novel Approaches to First-line Therapy for HER2-Positive Metastatic Breast Cancer

    Apr 17

    Experts Discuss Novel Approaches to First-line Therapy for HER2-Positive Metastatic Breast Cancer

    In this podcast episode, Erika Hamilton, MD, FASCO, and Ian Krop, MD, PhD, discuss recent developments in the field of first-line therapy and maintenance treatment for patients with HER2-positive metastatic breast cancer, including the following: Trastuzumab deruxtecan plus pertuzumab as first-line therapy based on data from DESTINY-Breast09 Adding palbociclib to HP and ET as maintenance therapy for HR-positive/HER2-positive MBC, based on data from PATINA Adding tucatinib to HP as maintenance therapy for HER2-positive MBC, based on data from HER2CLIMB-05 Presenters:  Erika Hamilton, MD, FASCO Chief Development Officer, Late Phase Director, Breast Cancer Research Program Sarah Cannon Research Institute (SCRI) Nashville, Tennessee Ian Krop, MD, PhD Professor of Medicine, Yale School of Medicine Associate Cancer Center Director for Clinical Research Yale Cancer Center New Haven, Connecticut Content based on an online CME program supported by an educational grant from Pfizer. Link to full program: https://bit.ly/4esvN9x  Get access to all our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    23 min
  8. Patient Voices: Caring for the Whole Patient and Personalizing Treatment of Early Breast Cancer to Achieve Equitable Outcomes

    Apr 15

    Patient Voices: Caring for the Whole Patient and Personalizing Treatment of Early Breast Cancer to Achieve Equitable Outcomes

    A patient advocate/cancer survivor and a healthcare professional discuss key topics including early breast cancer diagnosis, role of self-agency in pursuing optimal cancer care, encouraging trial participation with patient testimonials, and other considerations for the patient care journey such as appropriate screening, follow-up encounters for questions, guideline-based treatments, and side effect management.  Participants Kristen D. Whitaker, MD, MS Breast Medical Oncologist Medstar Georgetown Center Institute at Washington Hospital Center Assistant Professor of Medicine Georgetown University School of Medicine Washington, DC Asha Miller Founder, Asha Miller Creative Patient Advocate and Consultant Patient Experience and Health Equity Breast Cancer Veteran Columbus, Ohio Link to full program:https://bit.ly/47XIKV7 Get access to all our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    42 min
See All (248)

Ratings & Reviews

4.9
out of 5
10 Ratings

About

Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Decera Clinical Education. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.

Information

You Might Also Like